Divisional patent extends Phaxan™ patent portfolio to other neuroactive steroids in the U.S
MELBOURNE, AUSTRALIA: February 10, 2015—Drawbridge Pharmaceuticals Pty Ltd (Drawbridge) is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S Patent Application Number 14/069,751 entitled ‘Anaesthetic Formulation’ in the United States. This patent relates to a variety of neuroactive steroid anaesthetic/sedative compounds.
"Neuroactive steroids as a class possess a number of useful properties with respect to the pharmacological management of several CNS diseases. The expansion of the library of compounds available to us now opens up other development programs for Drawbridge,” said Professor Colin Goodchild, Chief Medical Officer at Drawbridge Pharmaceuticals.
Drawbridge's robust patent portfolio contains patents granted in U.S, U.K, Australia, New Zealand, Hong Kong, Singapore, South Africa and China for Phaxan™ anaesthesia and sedation. The allowance of the divisional patent in the United States to this portfolio extends the coverage to the use of a larger group of neuroactive steroids and preparations for sedation and anaesthesia in critical care situations. The new U.S patent compliments divisional patents recently granted in the UK and Australia.
“The Notice of Allowance for the divisional patent in the U.S adds significant value to the company extending coverage to a larger group of compounds for sedation and anaesthesia in critical care situations with coverage to 2031,” said Dr Anthony Filippis, CEO at Drawbridge Pharmaceuticals.
About Drawbridge Pharmaceuticals
Drawbridge Pharmaceuticals was founded in 2011. It is a privately-held biotechnology company, headquartered in Melbourne, Australia. The company is developing innovative neuroactive steroid compounds for use in critical care situations. Phaxan™ is the lead compound for use as a fast onset and offset intravenous general anaesthetic and sedative.
www.drawbridgepharmaceuticals.com.au
https://twitter.com/DrawbridgePharm
About Phaxan™
Phaxan™ is a novel water based formulation of the neuroactive steroid, alphaxalone. It has a wide therapeutic index, the widest ever described for any anaesthetic compound. Phaxan™ is an efficacious intravenous anaesthetic with rapid onset and offset of action. The anaesthetic agent in Phaxan™ has been administered in the past as Althesin® when formulated in a different excipient. It was withdrawn in 1984 because of problems with the formulation. Phaxan™ does not have the problems of the Althesin® formulation and it’s superiority in safety compared with propofol, has been demonstrated in preclinical and clinical trials.
Phaxan™ is a registered trademark for alphaxalone formulated in sulfobutyl ether beta cyclodextrin being developed by Drawbridge Pharmaceuticals.
Help employers find you! Check out all the jobs and post your resume.
MELBOURNE, AUSTRALIA: February 10, 2015—Drawbridge Pharmaceuticals Pty Ltd (Drawbridge) is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S Patent Application Number 14/069,751 entitled ‘Anaesthetic Formulation’ in the United States. This patent relates to a variety of neuroactive steroid anaesthetic/sedative compounds.
"Neuroactive steroids as a class possess a number of useful properties with respect to the pharmacological management of several CNS diseases. The expansion of the library of compounds available to us now opens up other development programs for Drawbridge,” said Professor Colin Goodchild, Chief Medical Officer at Drawbridge Pharmaceuticals.
Drawbridge's robust patent portfolio contains patents granted in U.S, U.K, Australia, New Zealand, Hong Kong, Singapore, South Africa and China for Phaxan™ anaesthesia and sedation. The allowance of the divisional patent in the United States to this portfolio extends the coverage to the use of a larger group of neuroactive steroids and preparations for sedation and anaesthesia in critical care situations. The new U.S patent compliments divisional patents recently granted in the UK and Australia.
“The Notice of Allowance for the divisional patent in the U.S adds significant value to the company extending coverage to a larger group of compounds for sedation and anaesthesia in critical care situations with coverage to 2031,” said Dr Anthony Filippis, CEO at Drawbridge Pharmaceuticals.
About Drawbridge Pharmaceuticals
Drawbridge Pharmaceuticals was founded in 2011. It is a privately-held biotechnology company, headquartered in Melbourne, Australia. The company is developing innovative neuroactive steroid compounds for use in critical care situations. Phaxan™ is the lead compound for use as a fast onset and offset intravenous general anaesthetic and sedative.
www.drawbridgepharmaceuticals.com.au
https://twitter.com/DrawbridgePharm
About Phaxan™
Phaxan™ is a novel water based formulation of the neuroactive steroid, alphaxalone. It has a wide therapeutic index, the widest ever described for any anaesthetic compound. Phaxan™ is an efficacious intravenous anaesthetic with rapid onset and offset of action. The anaesthetic agent in Phaxan™ has been administered in the past as Althesin® when formulated in a different excipient. It was withdrawn in 1984 because of problems with the formulation. Phaxan™ does not have the problems of the Althesin® formulation and it’s superiority in safety compared with propofol, has been demonstrated in preclinical and clinical trials.
Phaxan™ is a registered trademark for alphaxalone formulated in sulfobutyl ether beta cyclodextrin being developed by Drawbridge Pharmaceuticals.
Help employers find you! Check out all the jobs and post your resume.
